Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age

Inclusion Criteria: To be eligible for inclusion / randomization into this study, the subjects must fulfill all of the following criteria (if there is no inclusion phase, the inclusion criteria will be considered as inclusion criteria for randomization): * Written consent form signed by the parents / legal guardian, and child if possible * Subject born SGA and receiving a r-hGH therapy for this pathology * Recombinant human growth hormone (r-hGH) started at the maximal chronological age of 7 years for girls and 8 years for boys * Treatment with r-hGH started for at least 30 months and less than 36 months at 0.057 mg/kg/day * Height gain during the first 2 years of GH treatment \> 1 SD compared with the initial value Exclusion Criteria: To be eligible for inclusion in this study the subjects must not meet any of the following criteria: * Known hypersensitivity to Somatropin or any of the excipients * Active neoplasia (either newly diagnosed or recurrent) * Intracranial hypertension * Known diabetes mellitus * Proliferative or preproliferative diabetic retinopathy * Evidence of any progression or recurrence of an underlying intra-cranial space occupying lesion * Obesity defined as degree 1 on the corpulence curves * Precocious puberty * Pubertal status: Tanner breast development stage \> 2 for girls, and testicular volume \> 4 milliliter (mL) or testicular length \> 3 centimeter (cm) and/or testosterone value \>1 nanomole/liter \[nmol/L\] (0.29 gram/mL \[g/mL\]) for boys For girls \> 9 years and Tanner breast development stage 1: uterine size \> 35 millimeter (mm) * Severe chronic concomitant illness such as chronic renal failure, cystic fibrosis * Concomitant corticoid treatment or levothyroxine treatment other than substitutive treatment, topical or inhaled treatment * Participation to any clinical study within the 30 days preceding study entry